metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results	deaths (OS) E	progression or deaths (PFS) E	RFS/DFS E
mHNSCC - L2 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - all population
versus Standard of Care (SoC)
	nivolumab alone
	CheckMate 141, 2016 Oral Oncol 2017;73:138-146 Lancet Oncol 2017;18:1104-1115 Oral Oncol. 2018; 81:45-51 Oncologist 2018; 23:1079-1082 Cancer 2019; 125:3208-3218 Clin Cancer Res 2019; 25:5221-5230 Pharmacoeconomics 2019; 37:1041-1047 N Engl J Med. 2016 Nov 10;375(19):1856-1867 NCT02105636	RCT	mHNSCC - L2 - all population	nivolumab	ICC (methotrexate, docetaxel or cetuximab)	patients with recurrent squamous-cell carcinoma of the head and neck whose disease had progressed within 6 months after platinum-based chemotherapy	240 / 121	some concern	conclusif